Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances.

Published Friday in JAMA, scientists recently explored a risk-based mammography tactic that tailors regular imaging regimens to each individual’s danger of developing the disease. 

Alleged transgressions took place between February and August, including the FDA rejecting Telix’s application for a new brain cancer imaging agent.